Literature DB >> 18507552

Ranolozine-induced suppression of ventricular tachycardia in a patient with nonischemic cardiomyopathy: a case report.

David K Murdock1, Jeff Kaliebe, Naomi Overton.   

Abstract

Ranolazine is an antianginal agent, which inhibits the abnormal inward Na(+) current and by this inhibition decreases diastolic cardiomyocyte calcium levels and improves electrical stability. Ranolazine has also been shown to be a potent inhibitor of after depolarizations and triggered activity. In this case report, we describe the dramatic antiarrhythmic effects of ranolazine in a patient with nonischemic cardiomyopathy who had malignant ventricular tachycardia. Further research on the antiarrhythmic properties of ranolazine appears warranted.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18507552     DOI： 10.1111/j.1540-8159.2008.01083.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN： 0147-8389            Impact factor:   1.976


  8 in total

Review 1.  Usefulness of T-wave alternans in sudden death risk stratification and guiding medical therapy.

Authors:  Tuomo Nieminen; Richard L Verrier
Journal:  Ann Noninvasive Electrocardiol       Date:  2010-07       Impact factor: 1.468

Review 2.  Antiarrhythmic drugs 2013: state of the art.

Authors:  Kapil Kumar; Peter J Zimetbaum
Journal:  Curr Cardiol Rep       Date:  2013-10       Impact factor: 2.931

3.  Ranolazine for Atrial Fibrillation: Too Good to be True?

Authors:  Joseph J Gard; Samuel J Asirvatham
Journal:  J Atr Fibrillation       Date:  2010-08-23

4.  Electrophysiological Changes of the Atrium in Patients with Lone Paroxysmal Atrial Fibrillation.

Authors:  David K Murdock; James Reiffel; Jeff Kaliebe; German Larrain
Journal:  J Atr Fibrillation       Date:  2010-08-23

Review 5.  Electrophysiologic basis for the antiarrhythmic actions of ranolazine.

Authors:  Charles Antzelevitch; Alexander Burashnikov; Serge Sicouri; Luiz Belardinelli
Journal:  Heart Rhythm       Date:  2011-03-21       Impact factor: 6.343

6.  The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a review of experience with implications for possible "pill in the pocket" approach to atrial fibrillation.

Authors:  David K Murdock; Mary Kersten; Jeff Kaliebe; German Larrain
Journal:  Indian Pacing Electrophysiol J       Date:  2009-09-01

7.  Suppression of frequent ventricular ectopy in a patient with hypertrophic heart disease with ranolazine: a case report.

Authors:  David K Murdock; Jeffrey W Kaliebe
Journal:  Indian Pacing Electrophysiol J       Date:  2011-05-01

Review 8.  Impact of ranolazine on ventricular arrhythmias - A systematic review.

Authors:  George Bazoukis; Gary Tse; Konstantinos P Letsas; Costas Thomopoulos; Katerina K Naka; Panagiotis Korantzopoulos; Xenophon Bazoukis; Paschalia Michelongona; Stamatis S Papadatos; Konstantinos Vlachos; Tong Liu; Michael Efremidis; Adrian Baranchuk; Stavros Stavrakis; Costas Tsioufis
Journal:  J Arrhythm       Date:  2018-01-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.